US Patent Issued to Incyte on March 31 for "Ruxolitinib formulation for reduction of itch in atopic dermatitis" (Pennsylvania Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,589,096, issued on March 31, was assigned to Incyte Corp. (Wilmington, Del.).

"Ruxolitinib formulation for reduction of itch in atopic dermatitis" was invented by Michael Kuligowski (Chadds Ford, Pa.), Kang Sun (Wallingford, Pa.), Michael Howell (Kennett Square, Pa.), May Grace E. Venturanza (Chadds Ford, Pa.) and Jim Lee (Devon, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day."

The patent was filed on July 21, 2025, under Application No. 19/2...